

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

PC 02120

318471

<p style="text-align: center;">Licensee</p> <p>1. Cass Regional Medical Center Radiology Services</p> <p>2. 2800 Rock Haven Road Harrisonville, MO 64701</p>	<p>In accordance with the letters dated August 8, 2009, September 14, 2009, and September 22, 2009,</p> <p>3. License number 24-20234-02 is amended in its entirety as follows:</p> <hr/> <p>4. Expiration date August 31, 2012</p> <hr/> <p>5. Docket No. 030-29723 Reference No.</p>
--	---

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. As needed (not to exceed one curie of iodine-131)

9. Authorized Use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.**
 - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300 **(excluding sodium iodide iodine-131 for treatment of thyroid carcinoma)**.

CONDITIONS

- 10. Licensed material shall be used only at the licensee's facilities located at 1800 East Mechanic Street, Harrisonville, Missouri **and 2800 Rock Haven Road, Harrisonville, Missouri.**
- 11. Radiation Safety Officer: David F. Hazuka, M.D.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
24-20234-02

Docket or Reference Number
030-29723

Amendment No. 08

12. Licensed material is only authorized for use by, or under the supervision of:

- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
James E. Sear, M.D.	10 CFR 35.200.
David F. Hazuka, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding sodium iodide iodine-131 for treatment of thyroid carcinoma).
Stephen R. Kunz, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding sodium iodide iodine-131 for treatment of thyroid carcinoma).
Gwendolyn R. Arnett, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding sodium iodide iodine-131 for treatment of thyroid carcinoma).
Richard L. Cronemeyer, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding sodium iodide iodine-131 for treatment of thyroid carcinoma).
Robert F. Thompson, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding sodium iodide iodine-131 for treatment of thyroid carcinoma).
Thomas L. Rosamond, M.D.	10 CFR 35.200.
Timothy Blackburn, M.D.	10 CFR 35.200.
Kenneth M. Alfieri, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding sodium iodide iodine-131 for treatment of thyroid carcinoma).
Mark J. Lavin, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding sodium iodide iodine-131 for treatment of thyroid carcinoma).
Dipak Shah, M.D.	10 CFR 35.100 and 35.200.
Matthew R. Caterine, M.D.	10 CFR 35.100 and 35.200.
Ira Cox, M.D.	10 CFR 35.100, 35.200 and 35.300 (excluding sodium iodide iodine-131 for treatment of thyroid carcinoma).
Ronald Hublall, M.D.	10 CFR 35.100 and 35.200.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
24-20234-02Docket or Reference Number
030-29723


Amendment No. 08

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated February 28, 2002; and,
- B. Letter dated August 8, 2009 (excluding authorization request for Christopher McKinney, M.D.).**

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date SEP 25 2009

By


_____Colleen Carol Casey
Materials Licensing Branch
Region III